Elite Pharmaceuticals, Inc.
ELTP
$0.5475
-$0.0074-1.33%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 105.45M | 84.04M | 70.00M | 71.17M | 66.45M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 105.45M | 84.04M | 70.00M | 71.17M | 66.45M |
| Cost of Revenue | 46.61M | 43.96M | 39.09M | 39.34M | 36.37M |
| Gross Profit | 58.84M | 40.09M | 30.91M | 31.83M | 30.08M |
| SG&A Expenses | 10.66M | 9.23M | 9.43M | 8.40M | 7.65M |
| Depreciation & Amortization | 1.66M | 1.69M | 1.66M | 1.57M | 1.48M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 66.41M | 62.84M | 57.82M | 56.56M | 53.40M |
| Operating Income | 39.04M | 21.20M | 12.18M | 14.61M | 13.05M |
| Income Before Tax | -1.46M | -52.10K | -17.33M | -6.77M | 14.10K |
| Income Tax Expenses | 9.35M | 4.26M | 655.90K | -383.90K | -19.57M |
| Earnings from Continuing Operations | -10.82 | -4.31 | -17.99 | -6.39 | 19.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.82M | -4.31M | -17.99M | -6.39M | 19.58M |
| EBIT | 39.04M | 21.20M | 12.18M | 14.61M | 13.05M |
| EBITDA | 40.70M | 22.89M | 13.82M | 16.17M | 14.52M |
| EPS Basic | -0.01 | 0.00 | -0.02 | -0.01 | 0.02 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | 0.00 | -0.02 | -0.01 | 0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 4.27B | 4.27B | 4.22B | 4.17B | 4.12B |
| Average Diluted Shares Outstanding | 4.27B | 4.28B | 4.25B | 4.20B | 4.15B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |